Syntara Limited · ASX:SNT
Syntara — Investor Presentation (July 2024)
20 slides from Syntara's investor presentation, Jul 1, 2024
Slide 1: Investor Presentation
For personal use only ™ Investor Presentation Gary Phillips, CEO July 2024
Slide 2: Forward looking statement
Forward looking statement For personal use only This document contains involve known and unknown forward-looking statements, risks, uncertainties and other including statements factors, many of which are concerning Syntara’s future beyond our control, and which financial position, plans, and may cau
Slide 3: Global leaders in lysyl oxidase enzymes; Prioritising Myelofibrosis
For personal use only Global leaders in lysyl oxidase Prioritising Myelofibrosis (MF) • Market opportunities in excess of US$1b per enzymes with three Nature annum and recent history of biotech exits in publications and a pipeline of clinical excess of US$1.7b stage drugs in fibrosis and • SNT-5505
Slide 4: Shareholders & cash
Shareholders & cash Financial Information (ASX: SNT) Share Price & Volume - YTD For personal use only Share price – 27 June 2024 $0.022 Price (AUD) Market Cap A$27.5m $0.035 Cash balance (31 March 2024)1 A$7m $0.025 Enterprise value A$20.5m Note: $0.015 1. Additional funds receivable from acquiror o
Slide 5: Syntara Board — new leadership and downsized
Syntara Board — new leadership and downsized Significant international pharmaceutical experience For personal use only Dr Kathleen Metters Dr Simon Green Gary Phillips Hashan De Silva Chair Non-Executive Director Chief Executive Officer Non-Executive Director • Former Senior Vice President • Experie
Slide 6: Syntara is the global leader in lysyl oxidase chemistry and biology
Syntara is the global leader in lysyl oxidase chemistry and biology Multi year research program leveraged with extensive scientific collaborations worldwide has delivered For personal use only 3 drugs now in Phase 1c/2 studies Lysyl oxidases mediate the final stage in fibrosis SNT-5505 in Oncology T
Slide 7: Preclinical science and collaborations validated in high impact publications
Preclinical science and collaborations validated in high impact publications For personal use only Myelofibrosis Myelodysplastic • Treatment with Syndrome lysyl oxidase • In xenograft mouse inhibitor model that closely significantly resembles human reduced reticulin disease, SNT-5505 on fibrosis and
Slide 8: Myelofibrosis
Myelofibrosis A rare type of bone marrow cancer that disrupts the body's normal production of blood cells For personal use only Primary Myelofibrosis is characterised Current standard SNT-5505 Key Facts by a build up of scar tissue (fibrosis) in of care (SoC): JAK inhibition In contrast to SoC bone
Slide 9: SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures
SNT-5505 Phase 2a trial part 1; Monotherapy in JAK inhibitor treatment failures Demonstrates improvements in fibrosis grade, excellent safety profile and promising signs of clinical activity For personal use only Study Design Endpoints Trial Outlooks • IND approved Q3 2020 • SNT-5505 has been well •
Slide 10: Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor
Phase 2a study; SNT-5505 in patients on a stable dose of JAK inhibitor Fastest route to meaningful data with no dose escalation and utilising existing trial infrastructure Study Plan For personal use only • 19 clinical trial sites • Recruitment Treatment Cohort started 13 Dec Design Endpoints 2023 •
Slide 11: Strong interest in myelofibrosis assets from strategics
Strong interest in myelofibrosis assets from strategics Target / Acquiror / / For personal use only Date of Feb-2024 June-2023 July-2022 Announcement Drug Name Pelabresib Pacritinib Momelotinib Lead Indication / Myelofibrosis Myelofibrosis Myelofibrosis Phase (Successful Phase 3 (Marketed) (FDA File
Slide 12: Myelodysplastic Syndromes (MDS)
For personal use only Myelodysplastic Syndromes (MDS)
Slide 13: Myelodysplastic syndrome (MDS) is a blood cancer
Myelodysplastic syndrome (MDS) is a blood cancer Diverse bone marrow disorders characterized by inadequate production of healthy blood cells Key Facts 12–20k new cases are reported every Treatment of MDS For personal use only year in the US (87k p.a. worldwide) Current standard of care: Hypomethylat
Slide 14: Phase 1c/2a study in low and intermediate risk MDS
Phase 1c/2a study in low and intermediate risk MDS Grant funded investigator study with specialist CRO to deliver first results by mid 2025 Study organisation For personal use only • $0.83m grant from the Australian Medical Research Future Study Treatment Fund (MRFF). Patients Design Endpoints Popul
Slide 15: Skin Scarring
For personal use only Skin Scarring
Slide 16: Hypertrophic and keloid scarring
Hypertrophic and keloid scarring Cutaneous scarring following skin trauma or a wound is a major cause of morbidity and disfigurement For personal use only Key Facts • Mechanisms underlying scar • Pre clinical evidence formation are not well established; prophylactic and - Treatment with SNT-6302 100
Slide 17: SNT-6302 Phase 1c Trial in established skin scars (Solaria); Top line results
SNT-6302 Phase 1c Trial in established skin scars (Solaria 2); Top line results For personal use only SNT-6302 well tolerated Mean inhibition of LOX Meaningful changes in the Longer study required to and demonstrated a activity 66% compared to composition of the scars show appearance and good safety
Slide 18: Potential to deliver near term value
Potential to deliver near term value Pipeline creates multiple opportunities in high value markets For personal use only Addressable market Drug Candidate Indication Phase Upcoming Milestones (US$) Interim 6 month data Myelofibrosis (MF) Phase 2 ~$1 billion1 Q4 2024 SNT-5505 Myelodysplastic Syndrome
Slide 19: Recent & upcoming news flow
Recent & upcoming news flow Strong and growing pipeline with advancement in studies expected to provide value inflection points For personal use only COMPLETED COMPLETED COMPLETED Mid 2024 Mid 2024 Q4 2023 Q4 2023 Q4 2023 SNT-4728 iRBD / SNT-5505 Phase 2a SNT-5505 Phase 2a Pan-LOX scar SNT-5505 Phas
Slide 20: Contact details
For personal use only Gary Phillips Syntara Limited ABN 75 082 811 630 Chief Executive Officer gary.phillips@syntaraTX.com.au David McGarvey Chief Financial Officer david.mcgarvey@syntaraTX.com.au www.syntaraTX.com.au